Exenatide was the first drug of the GLP-1 class, and in the United States its record is now almost entirely historical. It was approved as Byetta in 2005 and as the once-weekly Bydureon in 2012, and its trials set questions the later drugs were measured against. When glp1ledger read FDA's Drugs@FDA database on 14 October 2026, every exenatide product — the generic included — was listed as discontinued.
How the molecule came from Gila monster venom is told on our Gila monster page, and its definition is in Peptide Lexicon's exenatide entry. This page is the product, trial and status record. It gives no dosing; dosage reporting for this molecule sits with Peptifact's exenatide dosage page.
The products, and what FDA lists now
| Product | Form | Application | Approved | Listed status, 14 Oct 2026 |
|---|---|---|---|---|
| Byetta | Twice-daily pen | NDA 021773 (AstraZeneca) | 28 Apr 2005 | Discontinued |
| Bydureon | Once-weekly, vial kit and pen | NDA 022200 (AstraZeneca) | 27 Jan 2012 | Discontinued |
| Bydureon BCise | Once-weekly autoinjector | NDA 209210 (AstraZeneca) | 20 Oct 2017 | Discontinued |
| Exenatide injection (generic of Byetta) | Twice-daily pen | ANDA 206697 (Amneal) | 19 Nov 2024 | Discontinued |
What changed this month. On 11 October 2026 the same database showed Amneal's generic as a prescription product, and glp1ledger reported it that way. By 14 October it showed both strengths as discontinued. The record also lists three labelling supplements for the generic approved on 2 October 2026. The database does not give the date a product stopped being sold, and we have not found a statement from Amneal; the listing is what we can report.
Two cautions on reading these records. A label on DailyMed is not proof a product is sold: on 14 October 2026 DailyMed still carried the Byetta label (AstraZeneca, effective 2025) and the Amneal label (published June 2026). And Drugs@FDA holds one stray record — a 2009 Byetta entry under Amylin Pharmaceuticals, the company that developed exenatide — that still shows "Prescription". It has had no submission since 30 October 2009 and is a filing for a new indication, not a separate product; the live Byetta application is the discontinued one above.
The trials that defined it
The twice-daily drug (Byetta). The label's three 30-week placebo-controlled trials added Byetta to metformin and/or a sulfonylurea in 963 people (483 on placebo). Its main effect was on blood sugar; its approved use was always type 2 diabetes, never weight management.
Weekly against twice daily (DURATION-1). 295 people with type 2 diabetes were randomised to the weekly 2 mg form or the twice-daily pen for 30 weeks. HbA1c fell -1.9 points on the weekly form against -1.5 on twice-daily (difference -0.54 to -0.12, p=0.0023), and 77% against 61% reached an HbA1c of 7.0% or less (Drucker et al., Lancet 2008). That result is why the weekly form was developed into Bydureon.
The heart (EXSCEL). 14,752 people with type 2 diabetes, 73% with previous cardiovascular disease, were followed for a median 3.2 years. Major cardiovascular events occurred in 11.4% on weekly exenatide against 12.2% on placebo (hazard ratio 0.91, 95% CI 0.83 to 1.00). That met the safety test (non-inferior, p<0.001) but missed superiority (p=0.06) — so, unlike liraglutide, semaglutide and dulaglutide, exenatide never gained a heart-protection claim on its label (Holman et al., NEJM 2017). The rates of pancreatitis, pancreatic cancer and medullary thyroid cancer did not differ significantly between the groups.
The side-effect record
From the Byetta label's pooled table for the three 30-week trials (adverse reactions at 2% or more and more common than on placebo):
| Reaction | Byetta (963) | Placebo (483) | Excess, points |
|---|---|---|---|
| Nausea | 44% | 18% | 26 |
| Vomiting | 13% | 4% | 9 |
| Diarrhoea | 13% | 6% | 7 |
| Feeling jittery | 9% | 4% | 5 |
| Dizziness | 9% | 6% | 3 |
| Headache | 9% | 6% | 3 |
| Dyspepsia | 6% | 3% | 3 |
Excess column: glp1ledger's subtraction of the two printed figures.
Without other diabetes drugs the picture was much milder: in the 24-week monotherapy trial nausea was 8% on Byetta against 0% on placebo. The two sets of trials enrolled different people on different background drugs, so the gap is not a measured effect of combination; the label does list low blood sugar as a separate risk when exenatide is combined with a sulfonylurea or insulin. The label also carries warnings for pancreatitis, kidney injury, a drug-induced drop in platelets and gallbladder disease. How these compare with the newer drugs is set out on GLP-1 side effects.
Why it faded
Exenatide's limits are visible in the record: a twice-daily injection with a short half-life (2.4 hours on the Byetta label), a weekly version that needed mixing before the BCise autoinjector, a cardiovascular trial that stopped short of a benefit, and no approval for weight management. Weekly drugs with heart-outcome claims and, later, obesity indications — dulaglutide, semaglutide, tirzepatide — overtook it. The molecule has not disappeared from research: ClinicalTrials.gov and PubMed still record trials of exenatide outside diabetes, including in idiopathic intracranial hypertension (summarised on our headache page).
For a list of every GLP-1 molecule and which are still sold, see which drugs are GLP-1s; for whether the newer drugs will follow exenatide into generics, see when will Ozempic go generic.
What is not established
- Why each product was discontinued, and when. Drugs@FDA records status, not reasons or dates.
- Whether pharmacies still hold stock. A discontinued listing describes the application, not shelves.
- Weight effect as a treatment. Exenatide was never tested or approved as a weight-management drug in the way the newer ones were.
Anyone currently prescribed exenatide, or told it is unavailable, is best advised by the prescriber or pharmacist on what replaces it.
Sources
- FDA Drugs@FDA, applications NDA 021773, NDA 022200, NDA 209210, NDA 021919 and ANDA 206697, via openFDA (dataset updated 2026-10-13) and the ANDA 206697 overview at accessdata.fda.gov, read 2026-10-14.
- BYETTA (exenatide) injection label, AstraZeneca, effective 2025-09-02 (set ID 53d03c03-ebf7-418d-88a8-533eabd2ee4f), sections 1, 6.1, Tables 2-3; exenatide injection, Amneal (set ID e6cb5c8f-e97f-4a6a-95a4-939fd2393949), both at dailymed.nlm.nih.gov, read 2026-10-14.
- Drucker DJ et al. "Exenatide once weekly versus twice daily for the treatment of type 2 diabetes." Lancet 2008;372:1240-50, PubMed 18782641 (NCT00308139).
- Holman RR et al. "Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes." NEJM 2017;377:1228-1239, PubMed 28910237.